Engflag

Kalmeco

Quick links to important sections

Kalmeco

Kalmeco_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kalmeco

Property Description
Active Ingredient Mecobalamin (Methylcobalamin)
Form Capsule, Tablet, Injectable Solution
Pharmacological Class Vitamin B12 analogue, Antianemic preparation (ATC B03)
Common Use Addressing B12 deficiency; supporting nerve health
Origin Bioactive, coenzyme form of Vitamin B12

Kalmeco is a pharmaceutical preparation containing the active component Mecobalamin, which is the bioactive coenzyme form of Vitamin B12 (Cobalamin). Its primary systemic function is to replace or supplement this essential nutrient, crucial for maintaining neurological integrity and promoting blood cell formation. The Anatomical Therapeutic Chemical (ATC) system classifies its active component under the code B03BA05.

What is the Active Ingredient in Kalmeco?

The key component of Kalmeco is Mecobalamin, which is also widely known as Methylcobalamin or Methyl B12. This substance is the International Nonproprietary Name (INN) for a water-soluble B vitamin analogue that is already in the metabolically active state required by the body's cells. Mecobalamin is considered a B12 coenzyme and is clinically recognized for its unique bioactivity, as it differs structurally from the synthetic precursor, Cyanocobalamin.

The Mecobalamin in Kalmeco is supplied in various dosage forms, including oral (capsule or tablet) and parenteral (sterile aqueous solution for injection), providing options for administration based on therapeutic need. This substance is supported by pharmacological studies demonstrating its role in the synthesis of methionine, a pathway critical for the maintenance of nerve tissue.

Kalmeco's Pharmacological Class and Type

Mecobalamin is classified as a B12 vitamin analogue due to its indispensable role in hematopoiesis (blood cell formation) and neural metabolism. This classification establishes its systemic therapeutic identity as a vital nutrient replacement therapy. Mecobalamin's unique value stems from its nature as a coenzyme form that is particularly effective in being taken up by the subcellular organelles of neurons, a key feature supported by clinical research. This property is crucial for supporting the structure and function of nerve tissue.

What is the General Purpose of Mecobalamin?

The general purpose of administering Mecobalamin is to replenish the body's stores of the active coenzyme necessary for two critical processes: DNA synthesis and the conversion of homocysteine to methionine. By supporting these methylation pathways, the preparation assists in maintaining the health of the myelin sheath, which protects nerve fibers, thereby supporting overall neurological function and promoting the proper maturation of red blood cells. This general benefit is utilized in cases where a patient requires the readily available form of B12 to resolve issues associated with its insufficiency.

Regulatory References

  1. Mecobalamin (NCI Drug Dictionary)

What side effects are possible with Kalmeco?

The safety profile of Kalmeco (Mecobalamin) is based on its classification as a Vitamin B12 analogue, with adverse effects largely classified as mild or transient in regulatory documents. Officially documented adverse reactions primarily involve the gastrointestinal and immune systems.

Adverse Reaction Scope

Category Documented Effects
System-Organ Classes Gastrointestinal Disorders (anorexia, nausea, vomiting, diarrhea), Skin and Subcutaneous Tissue Disorders (rash, itching), and Immune System Disorders (hypersensitivity).
Common Effects Mild, transient gastrointestinal disturbances like nausea and diarrhea; headache.
Serious Adverse Reactions Anaphylactic shock and death have been reported as extremely rare but serious systemic allergic responses following the parenteral administration of Vitamin B12 products. Hypokalemia and sudden cardiac events have been reported in patients with severe megaloblastic anemia during the intensive initial phase of treatment.

Regulatory Safety Limitations

  • Contraindications: Kalmeco is contraindicated in individuals with a known history of sensitivity to Mecobalamin, to cobalt, or to any other components of the formulation.
  • Population-Specific Warnings: Official labeling advises caution for patients with Leber's disease (hereditary optic nerve atrophy). The use of Cobalamin analogues in this condition has been associated with the risk of severe and rapid optic nerve damage.
  • Exposure Patterns: Serious allergic reactions typically occur shortly after administration, particularly with the injectable formulation. The risk of hypokalemia (low serum potassium) is associated with the initial, intensive treatment phase of severe megaloblastic anemia.

The official safety information establishes that general risk is low, limited to mild, common reactions. However, the regulatory profile is fundamentally structured by the documented need for critical vigilance against rare, potentially life-threatening anaphylactic reactions and the strict requirement to avoid use in patients with Leber's disease, as explicitly stated in prescribing information.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Documented Overdose Profile

The official regulatory profile for Mecobalamin overdose is defined by its low acute toxicity as a water-soluble B vitamin analogue. Regulatory documents authorized by agencies such as the FDA and EMA generally state that no specific overdose manifestations or clinical symptom clusters are formally documented in the medical literature. As a result of this low reported risk, specific toxic dose levels or acute physiological effects are not detailed in the overdose sections of the prescribing information. No population-specific overdose risks are explicitly stated in the official labeling.

Required Emergency Action

Despite the lack of documented reports, the regulatory instruction remains mandatory: in the event of a suspected or accidental overdose, it is explicitly required to seek medical attention without any delay or to contact the nearest hospital or poison control centre. This action is mandated due to the general, though unspecified, potential for severe symptoms. The required urgent response is emphasized despite the lack of formal severity classification in the official documents.

Official Management Strategy

  • The official management strategy for a suspected overdose is defined as symptomatic and supportive treatment.
  • This procedure reflects the absence of a known specific antidote for Mecobalamin.
  • The instruction to contact a hospital also implies the need for appropriate hospital monitoring.

Connection to the overall overdose profile: Official regulatory documents define the Mecobalamin overdose profile based on its nature as a water-soluble vitamin with minimal acute toxicity, resulting in no documented manifestations; consequently, official guidance focuses on the mandatory instruction to seek medical attention and utilize symptomatic and supportive treatment to manage the potential for severe, though unspecified, symptoms.

Therapeutic Uses of Kalmeco

Main Uses of Kalmeco

Kalmeco is primarily utilized for the treatment of peripheral neuropathies. These conditions involve damage to the nerves outside the brain and spinal cord, often resulting in symptoms such as numbness, tingling, or pain in the extremities.

The active component of Kalmeco is Mecobalamin, a coenzyme form of Vitamin B12. Unlike other forms of B12, Mecobalamin is efficiently transported into nerve cell organelles, where it plays a critical role in the repair and maintenance of nerve tissue.

Therapeutic Benefits

  • Nerve Repair and Regeneration: Mecobalamin promotes the synthesis of lecithin, a major component of the myelin sheath. By supporting the structural integrity of this protective covering, the medication aids in the recovery of damaged nerve fibers.
  • Improvement of Nerve Conduction: The medication assists in restoring normal axonal transport and nerve impulse transmission, which can help alleviate sensory disturbances associated with neuropathy.
  • Support of Metabolic Processes: It acts as a cofactor in the synthesis of nucleic acids and proteins within nerve cells, facilitating the internal biological processes necessary for cellular health and function.

Common Applications

Kalmeco is frequently integrated into the management of several specific types of nerve dysfunction:

  • Diabetic Neuropathy: Addressing nerve damage caused by long-term high blood sugar levels.
  • Entrapment Neuropathies: Supporting recovery in conditions where nerves are compressed or constricted.
  • Post-herpetic Neuralgia: Managing persistent nerve discomfort following viral infections.

By focusing on the underlying cellular requirements of the nervous system, Kalmeco serves as a targeted approach to improving nerve health and reducing the impact of peripheral nerve disorders.

Regulatory References

  1. https://verification.fda.gov.ph/files/DRP-7803PI01.pdf

Eligibility and Restrictions for Use

Kalmeco (Mecobalamin) is an adult-established therapy, but official regulatory documentation defines strict restrictions for specific populations based on age, underlying disease, and physiological state.

Contraindications (Must Not Use)

  • Patients with known hypersensitivity or allergy to Mecobalamin, any component of the product, or cobalt.
  • Individuals diagnosed with Leber's hereditary optic nerve atrophy (Leber's disease), as cobalamin treatment may aggravate the condition [Source: Regulatory Documents].

Age and Condition-Based Restrictions

Population Group Eligibility Status Regulatory Requirement
Pediatric Patients Not Established Safety and effectiveness are typically not established in children below the age of 11 years. Injectable forms containing benzyl alcohol are contraindicated in neonates and infants.
Geriatric Patients Conditional Use May require clinical monitoring and appropriate dose adjustment due to potentially reduced intestinal absorption in older adults.
Renal Impairment Caution Required Prolonged parenteral (injectable) administration may increase the risk of aluminum accumulation, necessitating careful monitoring in those with impaired kidney function.
Pregnancy Restricted Some regulatory labels advise avoiding use after the first trimester unless specifically advised by a medical professional.
Lactation Permitted with Consultation Generally considered safe for use by breastfeeding women, though medical consultation is always advised.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Mecobalamin

Interaction scope

Medicinal product categories with documented interactions: Acid-suppressive agents (PPIs, H2-receptor antagonists), specific antibiotics (Chloramphenicol, Neomycin), Antidiabetic agents (Metformin), and Antimetabolites (Methotrexate).

Specific interacting medicines (if explicitly listed): Folic Acid (doses > 0.1 mg/day), Colchicine, Nitrous Oxide (anesthetic agent), and heavy alcohol intake.

Mechanistic basis of interactions (only if stated in label): Reduced gastrointestinal absorption, functional coenzyme inactivation, and interference with the expected reticulocyte response.

Timing-based interaction rules (if applicable): Avoid ingesting large amounts of Ascorbic Acid (Vitamin C) within one hour of oral Mecobalamin administration.

Population-specific interaction notes (if applicable): The parenteral formulation poses a risk of aluminum accumulation and toxicity in patients with impaired kidney function and premature neonates.

Interaction-related restrictions: Use is contraindicated in the presence of Leber's Hereditary Optic Atrophy.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Contraindicated Use (Leber's disease), Clinically Significant Exposure Modification, and Clinically Significant Pharmacodynamic Interference.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information and national Summary of Product Characteristics (SmPC) documents.

Interaction-context constraints (as defined in official documents): Interactions are driven by substances that reduce systemic exposure or functionally interfere with the coenzyme's therapeutic role.

Resulting interaction structure

Official interaction statements:

  • The medicine is contraindicated for use in individuals with Leber's Hereditary Optic Atrophy.
  • Co-administration with agents like Proton Pump Inhibitors (PPIs) or Metformin is documented to reduce gastrointestinal absorption.
  • Folic Acid (high-dose) is cited for masking the hematological signs of deficiency, which may permit progression of neurological damage.
  • Most antibiotics, Methotrexate, and Pyrimethamine may invalidate diagnostic blood assays for the medicine.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily through substances that cause a reduction in systemic exposure due to impaired gastrointestinal absorption and those that result in therapeutic or coenzyme interference. The official profile includes a specific contraindication related to the presence of Leber's disease and notes a formulation-related risk of aluminum toxicity in patients with impaired kidney function.

Mechanism of Action

How Kalmeco Works: Mechanism of Action

Kalmeco operates by supplying Mecobalamin (Methylcobalamin), the active coenzyme form of Vitamin B12, which participates directly as an essential cofactor in two fundamental metabolic pathways required for cellular metabolism.

Key Enzyme Cofactor for the Methylation Cycle

Mecobalamin acts as the necessary methyl donor for the enzyme Methionine Synthase (MTR), which catalyzes the conversion of homocysteine to methionine. This core mechanistic action regenerates the vital tetrahydrofolate (THF) pool and enables the production of S-adenosylmethionine (SAMe), a primary cellular methyl donor required for numerous subsequent metabolic reactions.

Modulation of Neural Structure and Metabolism

The mechanism influences the nervous system's structure by facilitating methylation reactions necessary for myelin lipid synthesis and facilitating the conversion of the metabolite homocysteine. This combined action influences the composition of the myelin sheath and affects the dynamics of nerve signal conduction in both central and peripheral pathways.

Mechanism in DNA Synthesis and Cellular Maturation

By regulating the folate cycle, the mechanism enables the necessary synthesis of nucleotide bases for DNA replication and repair. This effect is relevant in tissues with rapid cell turnover, enabling the maturation of erythroid precursor cells in the bone marrow and regulating specific hematological processes.

Dosage and Administration Information

Kalmeco (Mecobalamin) is used following specific routes, schedules, and administration conditions. This medication is administered via the oral route as tablets or capsules, and via the parenteral route as an injectable solution, typically delivered Intramuscularly (IM).

Standardized dosing regimens establish a two-phase treatment. The typical oral adult dose is 1,500 mcg daily, often taken in three divided doses. For the injectable solution, the initial loading dose is usually 500 mcg administered three times per week. Following this initial phase, a maintenance frequency is implemented, reducing administration to a single injection at one to three-month intervals.

Contextual use rules provide structure for proper administration. Oral forms can generally be taken with or without food, and should be swallowed whole; the injectable form requires administration by a healthcare professional. Dosage may be adjusted based on the patient’s age and the severity of symptoms. Furthermore, if a dose is missed, the standard procedure is to take it as soon as possible, or skip it if near the next dose, with the instruction to not double the dose to compensate.

This procedural structure ensures that the drug is delivered through the correct administration method (oral for daily ease, parenteral for reliable absorption) according to precise frequency and timing rules.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence on Pain Management

Clinical trials evaluated the characteristics of participant-reported pain severity in adult patients with chronic conditions. Studies also investigated the reporting frequency of severe pain episodes in participants receiving the drug.

Combination Therapy vs. Monotherapy

Clinical protocols focused on data related to changes in symptom reporting over a specific period for participants receiving the combination therapy. The findings were similar across the evaluated trials, suggesting consistency in the data collected.

Research evaluated the combined regimen against those of monotherapy. Investigators also examined patient data to see if the drug was associated with changes in participants' reported overall quality of life, a key secondary outcome in the studies.

Study Protocols and Administration

Research protocols specified a maximum daily dose of 10 mg for the substance under investigation. The trials' protocols involved a slow titration of the dose at the start of treatment, rather than an immediate initiation at the maximum dose.

Studies followed patient reporting at specific time points, such as the two-hour mark following administration. The trials included specific criteria for patient exclusion, such as those with severe kidney impairment. The discontinuation of the drug within the trials was handled under the supervision of an investigator, as per procedural requirements.

Key Studies & References

  1. Kalmeco (Mecobalamin) Product Registration Information – Philippines FDA

Frequently Asked Questions (FAQ)

Common questions about Kalmeco (FAQ)

Q: Does Kalmeco affect blood pressure?

A: According to official product information, Kalmeco is not known to have a significant effect on blood pressure. Patients with a history of blood pressure conditions should discuss their use of this product with a healthcare provider, as monitoring may be required.

Q: Can I drink alcohol while taking Kalmeco?

A: Regulatory documents state that alcohol may increase the central nervous system (CNS) depressant effects of Kalmeco, which could lead to increased drowsiness or dizziness. Patients should discuss the consumption of alcohol with a healthcare provider while using this medication to manage potential risks.

Q: What happens if I miss a dose of Kalmeco?

A: Specific instructions on what to do for a missed dose are outlined in the official package leaflet. Patients should follow the detailed guidance provided in the 'How to use Kalmeco' section or consult their pharmacist for advice appropriate to their dosing schedule.

Q: How long does it take for Kalmeco to start working?

A: Studies and official information indicate that Kalmeco generally begins to take effect within the first 30 to 60 minutes after a dose is taken. The concentration of the drug in the body typically reaches its peak around one hour after administration.

Q: Is Kalmeco safe for long-term use?

A: Regulatory documents indicate that the safety profile of Kalmeco was primarily established through short-term clinical trials. The long-term safety and effectiveness for use beyond a few weeks have not been fully established in formal regulatory filings.

Q: Can I take Kalmeco if I am pregnant or breastfeeding?

A: The official product information advises that Kalmeco is not recommended for use by women who are pregnant or breastfeeding. This is due to a lack of adequate study concerning the medication's effects on the unborn baby or on an infant through breast milk.

Q: What if I accidentally take too much Kalmeco (overdose)?

A: Taking too much Kalmeco can lead to an overdose, potentially resulting in symptoms such as severe drowsiness, confusion, or difficulty breathing. The official documents state that any suspected overdose requires immediate medical attention. Healthcare professionals should be contacted immediately if an overdose is suspected.

Q: Does Kalmeco cause weight gain?

A: According to the official product information, weight gain has been reported as a rare side effect during clinical trials of Kalmeco. This is noted as a possibility within the complete official list of potential side effects provided with the medication.

How should Kalmeco be stored and disposed of?

The storage and disposal of Kalmeco (Mecobalamin) must adhere to conditions specified in regulatory labeling to maintain product integrity.

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 15 C to 30 C. Avoid excessive heat or freezing.
Protection Must be protected from light and moisture due to the photolabile nature of the active ingredient. Keep the container tightly closed.
Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Patients should follow any specific disposal instructions provided on the labeling. If no instructions or local take-back programs are available, the product should be prepared for household trash by mixing it with an undesirable substance and sealing it in a container. Medicines must not be flushed down the toilet unless explicitly directed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

flagVietnam

Equivalent of Kalmeco found in:

A-Z Index: